FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL |
|--------------|
| |

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

| | | | or Section 30(h) of the Investment Company Act of 1940 | |
|----------------------------------|------------|----------------|--|--|
| | | | 2. Issuer Name and Ticker or Trading Symbol BIOGEN INC. [BIIB] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify |
| (Last) BIOGEN INC. 225 BINNEY ST | | | 3. Date of Earliest Transaction (Month/Day/Year) 02/12/2016 | X Officer (give title Curier (specify below) EVP CMO Neuro & Neurodegenerat |
| (Street) CAMBRIDGE (City) | MA (State) | 02142 (Zip) | 4. If Amendment, Date of Original Filed (Month/Day/Year) | Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person |

| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | |
|--|--|---|--------------------------|---|--------|---------------|----------|---|---|---|--|--|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | Transaction Code (Instr. | | | | | 5. Amount of Securities Beneficially Owned Following Reported | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | Code | v | Amount | (A) or (D) | Price | Transaction(s) (Instr. 3 and 4) | | (111341.44) | | |
| Common Stock | 02/12/2016 | | F | | 628 | D | \$247.22 | 7,112 | D | | | |
| Common Stock | 02/12/2016 | | M | | 1,434 | A | \$0 | 8,546 | D | | | |
| Common Stock | 02/12/2016 | | F | | 556 | D | \$247.22 | 7,990 | D | | | |
| Common Stock | 02/12/2016 | | M | | 573 | A | \$0 | 8,563 | D | | | |
| Common Stock | 02/12/2016 | | F | | 270 | D | \$247.22 | 8,293 | D | | | |
| Common Stock | 02/12/2016 | | M | | 792 | A | \$0 | 9,085 | D | | | |
| Common Stock | 02/12/2016 | | F | | 373 | D | \$247.22 | 8,712 | D | | | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | 5. Number of Derivative Securities (A) or Disposed of (D) (Instr. 3, 4 and 5) | | ate Amount of | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
|---|---|--|---|------------------------------|---|---|-------|---------------------|--------------------|---|--|--|--|---|--|
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |
| Restricted Stock Unit | \$0 | 02/12/2016 | | М | | | 1,434 | (1) | 02/12/2019 | Common Stock | 1,434 | \$0 | 11,906 | D | |
| Restricted Stock Unit | \$0 | 02/12/2016 | | М | | | 573 | (2) | 02/12/2017 | Common Stock | 573 | \$0 | 2,095 | D | |
| Restricted Stock Unit | \$0 | 02/12/2016 | | М | | | 792 | (3) | 02/12/2017 | Common Stock | 792 | \$0 | 797 | D | |
| Restricted Stock Unit | \$0 | 02/12/2016 | | J ⁽⁴⁾ | | | 759 | (2) | 02/12/2017 | Common Stock | 759 | \$0 | 1,336 | D | |
| Restricted Stock Unit | \$0 | 02/12/2016 | | J ⁽⁴⁾ | | | 1,900 | (1) | 02/12/2019 | Common Stock | 1,900 | \$0 | 10,006 | D | |

Explanation of Responses:

- 1. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest each year for four years, beginning two years from the date of grant. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).
- 2. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).
- 3. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]).
- 4. This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

Jr.

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.